Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension

Abstract

Thiazolidinediones are a new class of antidiabetic agent that improve insulin sensitivity and reduce plasma glucose and blood pressure in subjects with type 2 diabetes1. Although these agents can bind and activate an orphan nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARγ), there is no direct evidence to conclusively implicate this receptor in the regulation of mammalian glucose homeostasis2. Here we report two different heterozygous mutations in the ligand-binding domain of PPARγ in three subjects with severe insulin resistance. In the PPARγ crystal structure, the mutations destabilize helix 12 which mediates transactivation. Consistent with this, both receptor mutants are markedly transcriptionally impaired and, moreover, are able to inhibit the action of coexpressed wild-type PPARγ in a dominant negative manner. In addition to insulin resistance, all three subjects developed type 2 diabetes mellitus and hypertension at an unusually early age. Our findings represent the first germline loss-of-function mutations in PPARγ and provide compelling genetic evidence that this receptor is important in the control of insulin sensitivity, glucose homeostasis and blood pressure in man.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Two new mutations, P467L and V290M, in human PPARγ.
Figure 2: Functional properties of the P467L and V290M mutant receptors.
Figure 3: Pro?467 and Val?290 are important in defining the orientation of helix 12.

References

  1. Day,C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med. 16, 179–192 (1999).

    Article  CAS  Google Scholar 

  2. Spiegelman,B. M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507–514 (1998).

    Article  CAS  Google Scholar 

  3. Hattersley,A. T. Maturity onset diabetes of the young; clinical heterogeneity explained by genetic heterogeneity. Diabetic Med. 15, 15–24 (1998).

    Article  CAS  Google Scholar 

  4. Flier,J. S. Syndromes of insulin resistance—from patient to gene and back again. Diabetes 41, 1207–1219 (1992).

    Article  CAS  Google Scholar 

  5. Krook,A. et al. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 43, 357–368 (1994).

    Article  CAS  Google Scholar 

  6. Whitehead,J. P. et al. Molecular scanning of the insulin receptor substrate 1 gene in subjects with severe insulin resistance. Diabetes 47, 837–839 (1998).

    Article  CAS  Google Scholar 

  7. Tontonoz,P., Hu,E. & Spiegelman,B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).

    Article  CAS  Google Scholar 

  8. Lehmann,J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270, 12953–12956 (1995).

    Article  CAS  Google Scholar 

  9. Willson,T. M. et al. The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. 39, 665–668 (1996).

    Article  CAS  Google Scholar 

  10. Matthews,D. R. et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985).

    Article  CAS  Google Scholar 

  11. Danielian,P. S., White,R., Lees,J. A. & Parker,M. G. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J. 11, 1025–1033 (1992).

    Article  CAS  Google Scholar 

  12. Chakravarti,D. et al. Role of CBP/P300 in nuclear receptor signalling. Nature 383, 99–103 (1996).

    Article  ADS  CAS  Google Scholar 

  13. Di Renzo,J. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators and corepressors. Mol. Cell. Biol. 17, 2166–2176 (1997).

    Article  CAS  Google Scholar 

  14. Mukherjee,R. et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407–410 (1997).

    Article  ADS  CAS  Google Scholar 

  15. Collingwood,T. N., Adams,M., Tone,Y. & Chatterjee,V. K. K. Spectrum of transcriptional dimerization and dominant negative properties of twenty different mutant thyroid hormone β receptors in thyroid hormone resistance syndrome. Mol. Endocrinol. 8, 1262–1277 (1994).

    CAS  PubMed  Google Scholar 

  16. Desbois,C. et al. A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors. Cell 67, 731–740 (1991).

    Article  CAS  Google Scholar 

  17. Nolte,R. T. et al. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395, 137–143 (1998).

    Article  ADS  CAS  Google Scholar 

  18. Ristow,M. et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl. J. Med. 339, 953–959 (1998).

    Article  CAS  Google Scholar 

  19. Adams,M. et al. Transcriptional activation by peroxisome proliferator-activated receptor γ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J. Biol. Chem. 272, 5128–5132 (1997).

    Article  CAS  Google Scholar 

  20. Beamer,B. A. et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes 47, 1806–1808 (1998).

    Article  CAS  Google Scholar 

  21. Deeb,S. S. et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genet. 20, 284–287 (1998).

    Article  CAS  Google Scholar 

  22. Sarraf,P. et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol. Cell 3, 799–804 (1999).

    Article  CAS  Google Scholar 

  23. Libby,P. et al. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19, 546–551 (1999).

    Article  Google Scholar 

  24. Iijima,K. et al. Expression of peroxisome proliferator-activated receptor γ (PPARγ) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Comm. 247, 353–356 (1998).

    Article  CAS  Google Scholar 

  25. Ogihara,T., Rakugi,H., Ikegama,H. et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hyperten. 8, 316–320 (1995).

    Article  CAS  Google Scholar 

  26. Nakamura,Y. et al. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol. 123, 675–682 (1998).

    Article  CAS  Google Scholar 

  27. Satoh,H. et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: A new possible role of PPARγ on vascular endothelial function. Biochem. Biophys. Res. Comm. 254, 757–763 (1999).

    Article  CAS  Google Scholar 

  28. Doi,K. et al. PPARγ modulates endothelial function: effects of thiazolidinediones on endothelial cell growth and secretion of endothelin (ET) and C-type natriuretic peptide (CNP). Circulation 98, 192 (1998).

    Google Scholar 

  29. Young,P. W. et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J. Pharmacol. Exp. Ther. 284, 751–759 (1998).

    CAS  PubMed  Google Scholar 

  30. Forman,B. M. et al. 15-Dexoy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83, 803–812 (1995).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

M. Gurnell is a Wellcome Training Fellow, and S. O'Rahilly and K. Chatterjee are supported by the Wellcome Trust. We thank M. Flynn, A. Marshall and J. Keogh for assistance with clinical investigations, A. Rudenski for HOMA analysis, and S. Smith (SmithKline Beecham) for PPAR γ ligands. Among the many people at Incyte Europe involved in this project, we thank C. Baynes and J. Lightning for sequencing, I. Loudon for project management support; P. Weller and E. Génin for paternity testing and analysis, and C. Luccarini and D. Townley for PPARγ genomic structure determination.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. O'Rahilly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barroso, I., Gurnell, M., Crowley, V. et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880–883 (1999). https://doi.org/10.1038/47254

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/47254

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing